9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Estimated reading time: < 1 min

Condition: Advanced Malignant Mesothelioma

Estimated Enrollment: 13

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee,  Overall Survival,  Progression-free Survival, Toxicity Profile

Interventions: belinostat, laboratory biomarker analysis

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 2009

Completion Date: March 2009

Last  Posted Date: June 7, 2018

Location: City of Hope, Duarte, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT00365053

Was this article helpful?
Dislike 0